Year: 2026
Type: article
Abstract: BACKGROUND: In recent decades, autologous cellular plasma therapy (CPT) has become a promising treatment for musculoskeletal conditions due to the ability of activated blood cells to release growth factors, anti-inflammatory, and analgesic cytokines. However, the high cost of foreign consumables and equipment limits treatment accessibility. AIM: To compare a new a new Russian plasma preparation (LR-PRP) technology for musculoskeletal conditions with the foreign RegenLab (RL) technology (RegenLab technology is registered and approved; Reg. No. FSZ 2011/10571, dated December 30, 2011; Reg. No. FSZ 2011/10570, dated September 15, 2011; and Reg. No. FSZ 2011/11417, dated December 30, 2011) technology in terms of production methods, activation methods, and cellular composition of the resulting preparations. METHODS: We conducted an experimental, open-label, prospective study. Between March 2024 and May 2025, we compared the two preparations—LR-PRP and PRP (RL)—by production methods, cellular composition, and activation method. The study involved 20 patients aged 25 to 58 years with musculoskeletal conditions, from whom 10 mL of blood was drawn. CPT preparations were prepared and studied using the new Russian technology (12 patients) and the RL technology (8 patients). RESULTS: LR-PRP contains platelets, leukocytes, and erythrocytes, providing a broader range of biologically active substances than PRP (RL), which contains only platelets. Cellular composition analysis showed that the domestic technology allows controlled preparation of products with both high and low cell concentrations. Activation with calcium chloride (CaCl₂) enhances growth factor release, including red blood cell hemolysis products and microvesicles, which increases regenerative potential. Comparison showed advantages of LR-PRP: cost-effectiveness, ease of use, preservation of biologically active substances activity through low-temperature sedimentation, and avoidance of mechanical cell damage. However, further studies on dosage, activation, and effectiveness in various conditions are needed to optimize clinical use. CONCLUSIONS: Thus, the new import-substituting technology for obtaining cell plasma therapy preparations is a promising alternative to imported PRP preparations, combining availability, ease of preparation, physiological properties and a wide range of obtained biologically active substances.
DOI: 10.17816/vto680547
Institution: Russian Railways
Language: English
Subfield: Periodontics
Field: Dentistry
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7204231136